A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflamma...
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with ...
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glome...
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the effi...
Belimumab With Rituximab for Primary Membranous Nephropathy
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituxim...
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN...
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein cr...
AMPK-activation by Metformin in FSGS: AMP-FSGS
The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte surv...
Top Cities for Nephrotic Syndrome Clinical Trials
Nephrotic Syndrome clinical trials are recruiting across 52 cities. Here are the cities with the most active studies:
About Nephrotic Syndrome
Nephrotic syndrome is a kidney disorder characterized by heavy proteinuria, low blood albumin, high cholesterol, and swelling. It can be caused by various underlying conditions. Treatment targets the underlying cause and may include immunosuppressive medications and supportive care.
Clinical trials are advancing new treatments for nephrotic syndrome. Currently, 8 studies are recruiting a combined 1,059 participants across the United States. Research is being conducted by 8 organizations including Dimerix Bioscience Pty Ltd, BeiGene, Biogen and 5 others.
2026 Nephrotic Syndrome Research Landscape
As of March 2026, the nephrotic syndrome clinical trial landscape includes 8 actively recruiting studies across 52 cities in the United States. These studies are collectively seeking 1,059 participants, with an average enrollment target of 132 per study.
Research is being led by 8 different organizations, including Dimerix Bioscience Pty Ltd, BeiGene, Biogen, Cerium Pharmaceuticals, Inc., National Institute of Allergy and Infectious Diseases (NIAID), and 3 others.
Geographically, nephrotic syndrome trials are most concentrated in Los Angeles, California (4 trials); Northridge, California (3 trials); Miami, Florida (3 trials); Birmingham, Alabama (2 trials); Phoenix, Arizona (2 trials) and 7 other cities.
Featured Nephrotic Syndrome Studies
Highlighted recruiting studies for nephrotic syndrome, selected by enrollment size and research scope.
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with pla...
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care.
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type of antibody that mistakenly targets and attacks the body's own tissues. Glomeruli are the ...
Frequently Asked Questions About Nephrotic Syndrome Clinical Trials
Are there nephrotic syndrome clinical trials near me?
Yes, there are 8 nephrotic syndrome clinical trials currently recruiting across 52+ cities in the United States, including Los Angeles, California; Northridge, California; Miami, Florida. Browse the studies above to find one at a location convenient for you.
How do I join a nephrotic syndrome clinical trial?
To join a nephrotic syndrome clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are nephrotic syndrome clinical trials free?
Yes, participation in nephrotic syndrome clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of nephrotic syndrome treatments are being studied?
Current nephrotic syndrome clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 8 research organizations.
Is it safe to participate in nephrotic syndrome clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov